Transaction · 0001493152-26-047454

Gaslightwala Abizer

Gaslightwala Abizer, CEO, reported a transaction classified as grant at Akari Therapeutics Plc involving 174000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 174000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
AKTXAkari Therapeutics Plc
Trade date
Aug 18, 2026
Filing date
Oct 16, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded174k$0.00 per share
Holdings after174kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 59 calendar days after the transaction date.

AKTX price since this filing

Daily closing prices, with the filing date and available return windows
AKTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +34.6%1w ago -5.5%1d ago -8.1%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001493152-26-047454
Stock Option (Right to Buy)
Transaction date
Aug 18, 2026
Filed Oct 16, 2026, 09:20 PM · 59d delay
Shares
174,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
174,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Delayed Filing Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-16 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • delayed_filing-6 points

    reporting_delay_days = 59

    Filing delay exceeds the configured threshold.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed…

  2. F2

    The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.

  3. F3

    The pre-funded warrants remain exercisable until fully exercised.

  4. F4

    On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all ac…

  5. F5

    On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Privat…

  6. F6

    The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.

Original filing · 0001493152-26-047454
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

AKTX